Testing IAG933 for advanced mesothelioma and other solid tumors

An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors

This study is testing a new treatment called IAG933 to see if it is safe and can help people with advanced mesothelioma and other solid tumors that haven't responded to standard treatments.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 156 (estimated)
• Ages: 18 Years to 120 Years
• Sex: All
• Sponsor: Novartis (Industry-sponsored)
• Drugs / interventions: radiation
• Locations: 17 sites (Los Angeles, California and 16 other locations)
• Trial ID: NCT04857372 on ClinicalTrials.gov

What this trial studies

This phase I study evaluates the safety and tolerability of IAG933 in patients with advanced mesothelioma and other solid tumors characterized by specific genetic mutations. The study consists of a dose escalation phase to determine the maximum tolerated dose, followed by a dose expansion phase to assess preliminary anti-tumor activity in defined patient populations. Participants must have tumors that have not responded to standard therapies or for which no standard treatment is available.

Who should consider this trial

Good fit: Ideal candidates include adults with advanced mesothelioma or solid tumors with specific genetic alterations who have failed standard therapies.

Not a fit: Patients with early-stage tumors or those who have not yet undergone standard treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced mesothelioma and specific genetic tumor profiles.

How similar studies have performed: Other studies targeting similar genetic mutations have shown promise, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.
2. Male or female patients must be ≥ 18 years of age.
3. Dose escalation part: patients with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma or other solid tumors. Patients with solid tumors other than mesothelioma must have local available data for loss-of-function NF2/LATS1/LATS2 genetic alterations (truncating mutation or gene deletion; LATS1/LATS2 mutations will only be included in the dose escalation part), or functional YAP/TAZ fusions. Patients with malignant EHE can be enrolled with only histological confirmation of the disease. Patients must have failed available standard therapies, be intolerant of or ineligible for standard therapy, or for whom no standard therapy exists.
4. Dose expansion part: the following patients will be enrolled into 3 different treatment groups:

   Group 1: Advanced (unresectable or metastatic) MPM patients who have failed available standard therapies for advanced/metastatic disease, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

   Group 2: Advanced (unresectable or metastatic) solid tumor patients with available local data for NF2 truncating mutation or deletions. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

   Group 3: Advanced (unresectable or metastatic) solid tumor patients with available local data for functional YAP/TAZ fusions. EHE patients can be included with only histological confirmation of the disease. Patient must have failed available standard therapies, be intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.

   Group 4: Advanced (unresectable or metastatic) non-pleural mesothelioma patients who have failed available standard therapies for advanced/metastatic disease, are intolerant or ineligible to receive such therapy, or for whom no standard therapy exists.
5. Presence of at least one measurable lesion according to mRECIST v1.1 for mesothelioma patients, RECIST v1.1 for patients with other solid tumors, or RANO for patients with primary brain tumors.
6. Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study. An archival tumor sample may be used at screening. During the dose expansion part of the study, a decision may be made to stop the collection of on-treatment biopsies.

Exclusion Criteria:

1. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment within the stated timeframes:

   1. ≤ 4 weeks for thoracic radiotherapy to lung fields or limited field radiation for palliation within ≤ 2 weeks prior to the first dose of study treatment. An exception to this exists for patients who have received palliative radiotherapy to bone, who must have recovered from radiotherapy-related toxicities but for whom a 2-week washout period is not required.
   2. ≤ 4 weeks or ≤ 5 half-lives (whichever is shorter) for biological therapy (including monoclonal antibodies) or continuous or intermittent small molecule therapeutics or any other investigational agent.
   3. ≤3 weeks for treatment with cytotoxic agents or ≤ 6 weeks for cytotoxic agents with risk of major delayed toxicities, such as nitrosoureas and mitomycin C.
   4. ≤ 4 weeks for immuno-oncologic therapy, such as CTLA4, PD-1, or PD-L1 antagonists
   5. Prior treatment with TEAD inhibitor at any time
2. For mesothelioma patients: use of non-invasive antineoplastic therapy (e.g., tumor treating fields, brand name Optune LuaTM) within 2 weeks of the tumor assessment at screening.
3. Malignant disease, other than that being treated in this study.
4. Insufficient renal function at Screening.
5. Clinically significant cardiac disease or risk factors at screening
6. Insufficient bone marrow function at screening.
7. Insufficient hepatic function at screening.
8. Patients who have the following laboratory values \> Common Terminology Criteria for Adverse Events (CTCAE) grade 1:

   1. Potassium
   2. Magnesium
   3. Total calcium (corrected for low serum albumin)
9. Known active COVID-19 infection.
10. Pregnant or nursing (lactating) women,
11. Japan only: patients with a history of drug- and/or non-drug-induced interstitial lung disease (ILD) ≥ Grade 2.

Other protocol-defined inclusion/exclusion criteria may apply.

Where this trial is running

Los Angeles, California and 16 other locations

• University of California LA — Los Angeles, California, United States (Recruiting)
• Uni of Chi Medi Ctr Hema and Onco — Chicago, Illinois, United States (Recruiting)
• Sidney Kimmel CCC At JH — Baltimore, Maryland, United States (Recruiting)
• Massachusetts General Hospital Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
• Cleveland Clinic Foundation — Cleveland, Ohio, United States (Recruiting)
• MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
• Novartis Investigative Site — Melbourne, Victoria, Australia (Recruiting)
• Novartis Investigative Site — Montreal, Quebec, Canada (Recruiting)
• Novartis Investigative Site — Villejuif, France (Recruiting)
• Novartis Investigative Site — Essen, Germany (Recruiting)
• Novartis Investigative Site — Milano, Mi, Italy (Recruiting)
• Novartis Investigative Site — Rozzano, Mi, Italy (Recruiting)
• Novartis Investigative Site — Chuo ku, Tokyo, Japan (Recruiting)
• Novartis Investigative Site — Rotterdam, Zuid Holland, Netherlands (Recruiting)
• Novartis Investigative Site — Barcelona, Catalunya, Spain (Recruiting)
• Novartis Investigative Site — Zuerich, Switzerland (Recruiting)
• Novartis Investigative Site — Manchester, United Kingdom (Recruiting)

Study contacts

• Study coordinator: Novartis Pharmaceuticals

Conditions Mesothelioma; IAG933; NF2 mutated tumors; LATS1/LATS2 mutated tumors; YAP/TAZ